GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
65.04
-2.17 (-3.23%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close67.21
Open67.52
Bid64.50 x 1800
Ask66.36 x 1100
Day's Range64.91 - 67.53
52 Week Range60.32 - 79.61
Volume8,876,391
Avg. Volume6,474,109
Market Cap82.702B
Beta (3Y Monthly)1.15
PE Ratio (TTM)14.35
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.52 (3.75%)
Ex-Dividend Date2019-06-13
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire3 days ago

    Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

    Gilead Sciences, Inc. (GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales.

  • Business Wire4 days ago

    Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019

    Gilead Sciences, Inc. today announced that new data from the company’s HIV research and development programs will be presented at the 10th International AIDS Society Conference on HIV Science being held in Mexico City from July 21-24.

  • Business Wire5 days ago

    Gilead Sciences Announces Changes to Senior Leadership Team

    Gilead Sciences, Inc. (GILD) announced today changes to the company’s senior leadership team. Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing Gilead. Jyoti Mehra has been named Executive Vice President, Human Resources, and will assume responsibility for the worldwide HR function.

  • Business Wire5 days ago

    Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company

    Gilead Sciences, Inc. (GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month. Dr. McHutchison joined Gilead in 2010 and under his leadership, Gilead has developed five medicines that have been used by more than 3.2 million people around the world for the curative treatment of chronic hepatitis C, and treatment of chronic hepatitis B. He also oversaw the company’s expansion into oncology with the development of Gilead’s first cancer medicine, Zydelig® (idelalisib). During his tenure, he has been responsible for broadening and overseeing the company’s Research and Development pipeline, advancing candidates in new therapeutic areas, including oncology, cell therapy and inflammation.

  • Business Wire6 days ago

    Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019

    Gilead Sciences, Inc. (GILD) announced today that its second quarter 2019 financial results will be released on Tuesday, July 30, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2019 and provide a business update. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 8696029 to access the call.

  • Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
    Business Wire6 days ago

    Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility

    Kite, a Gilead Company , today announced plans for a new 67,000-square-foot facility in Oceanside, California, dedicated to the development and manufacturing of viral vectors, a critical starting material in the production of cell therapies.

  • GlobeNewswire8 days ago

    GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION

    - Gilead to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment - - Gilead Gains Access to Galapagos` Differentiated Drug Discovery Platform and Current and Future Pipeline Outside of ...

  • Business Wire8 days ago

    Gilead and Galapagos Enter Into Transformative Research and Development Collaboration

    Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that they have entered into a 10-year global research and development collaboration. Through this agreement, Gilead will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform.

  • Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite
    Business Wire11 days ago

    Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite

    Gilead Sciences, Inc. (GILD) today announced that Christi L. Shaw will join the company as Chief Executive Officer of Kite, a Gilead Company, and will become a member of Gilead’s senior leadership team. Prior to joining Lilly, Ms. Shaw most recently served as U.S. Country Head and President of Novartis Corp. and North American Head of Novartis Oncology.

  • Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)
    Business Wire11 days ago

    Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)

    Gilead Sciences, Inc. (GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada.

  • GlobeNewswire20 days ago

    GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR

    As a result of this discussion, a path forward has been established to submit the NDA for filgotinib as a treatment for rheumatoid arthritis in 2019. Filgotinib is an investigational agent and not approved anywhere globally. Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases.

  • Business Wire21 days ago

    Gilead Announces Intent to Submit New Drug Application for Filgotinib to U.S. Food and Drug Administration This Year

    Gilead Sciences, Inc. (GILD) today announced that at a recent pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA), the company provided an update about the investigational, oral, selective JAK1 inhibitor filgotinib. As a result of this discussion, a path forward has been established to submit the NDA for filgotinib as a treatment for rheumatoid arthritis in 2019. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.

  • Business Wire26 days ago

    Louisiana Launches Hepatitis C Innovative Payment Model With Asegua Therapeutics, Aiming to Eliminate the Disease

    Today, Governor John Bel Edwards joined Secretary Rebekah Gee of the Louisiana Department of Health, Secretary James LeBlanc of the Louisiana Department of Corrections, and Asegua Therapeutics LLC, a wholly-owned subsidiary of Gilead Sciences, Inc. (GILD), to announce a deal that will allow the implementation of an innovative payment model for hepatitis C treatment, part of Louisiana’s plan to eliminate the disease.

  • Business Wire28 days ago

    Gilead and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies

    Gilead Sciences, Inc. (GILD) and Carna Biosciences Inc. (JASDAQ:4572) today announced that the companies have entered into a research and development collaboration to develop and commercialize small molecule compounds in immuno-oncology and to access Carna’s proprietary lipid kinase drug discovery platform. Under the terms of the license agreement, Gilead will license from Carna worldwide rights to develop and commercialize inhibitors against an undisclosed immuno-oncology target. In connection with this agreement, Carna will receive an upfront payment of $20 million and is eligible to receive up to an additional $450 million in potential milestone payments upon achievement of certain development and commercial milestones.

  • Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases
    Business Wirelast month

    Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases

    Gilead Sciences, Inc. (GILD) and Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases. Dysregulated and/or mutated proteins play a central role in the development and progression of many human diseases. Nurix’s technology platform is focused on the manipulation of the ubiquitin system and its component E3 ligases, the key enzymes responsible for controlling protein levels in human cells.

  • CNW Grouplast month

    GT Biopharma Company Update

    GT Biopharma Company Update

  • Kite Announces New Yescarta® Data From ZUMA-1
    Business Wire2 months ago

    Kite Announces New Yescarta® Data From ZUMA-1

    -- Sub-Population Analysis Demonstrates High Rates of Durable Response and Overall Survival Regardless of Age at Two Years Post-Treatment --

  • Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
    Business Wire2 months ago

    Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

    ZUMA-3 is a single-arm Phase 1/2 study in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The results provide guidance on dosing and safety management for KTE-X19 to inform the ongoing Phase 2 study. Patients enrolled in this study were primary refractory or relapsed/refractory after at least two prior lines of therapy.

  • GlobeNewswire2 months ago

    Biocartis Group NV: Biocartis and Kite Sign Agreement for Development of Assays supporting Kite's Therapies

    Biocartis Group NV (the `Company` or `Biocartis`), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company (a pharmaceutical company engaged in the development of innovative cancer cell therapies). The agreement is aimed at the development of molecular-based assays on Biocartis` molecular diagnostics Idylla(TM) platform that are supportive to Kite`s therapies.

  • GlobeNewswire2 months ago

    Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Kite, a Gilead Company (GILD) and Humanigen, Inc., (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Kite will act as the sponsor of this study and will be responsible for its conduct. GM-CSF has been identified, through clinical correlative analysis and preclinical modeling, as a potential key signal in the inflammatory cascade triggering toxicities associated with chimeric antigen receptor T (CAR T) cell therapy.1 Toxicities associated with CAR T therapy include neurologic toxicity and cytokine release syndrome (CRS).

  • Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Business Wire2 months ago

    Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Kite, a Gilead Company (GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Kite will act as the sponsor of this study and will be responsible for its conduct. GM-CSF has been identified, through clinical correlative analysis and preclinical modeling, as a potential key signal in the inflammatory cascade triggering toxicities associated with chimeric antigen receptor T (CAR T) cell therapy.1 Toxicities associated with CAR T therapy include neurologic toxicity and cytokine release syndrome (CRS).

  • GlobeNewswire2 months ago

    GILEAD AND GALAPAGOS TO PRESENT LATEST DATA ON FILGOTINIB AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR 2019)

    -- Phase 3 FINCH 1 and FINCH 3 Data of Filgotinib in Rheumatoid Arthritis to Be Featured in Opening Plenary and Late Breaker Sessions -- Foster City, Calif. and Mechelen, Belgium; May 29, 2019; 22.30 CET ...

  • Business Wire2 months ago

    Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)

    Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, oral, selective JAK1 inhibitor, will be presented at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain, on June 12-15, 2019. Among the abstracts to be presented are 24 week interim results from the ongoing FINCH 1 and FINCH 3 Phase 3 studies evaluating filgotinib in adults with rheumatoid arthritis.

  • Business Wire2 months ago

    Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer

    Gilead Sciences, Inc. (GILD) today announced that Johanna Mercier will join the company as Chief Commercial Officer, and will become a member of the company’s senior leadership team. Ms. Mercier will assume responsibility for the company’s commercial operations effective July 1. Laura Hamill, Executive Vice President Worldwide Commercial Operations, will be departing from Gilead.